

STAT3(Phospho-Tyr705) Antibody

Catalog No: #11045



Package Size: #11045-1 50ul #11045-2 100ul #11045-4 25ul

Overview

Product Name	STAT3(Phospho-Tyr705) Antibody
Host Species	Rabbit
Clonality	Polyclonal
Applications	WB IHC IF
Species Reactivity	Hu Ms Rt
Immunogen Type	Peptide-KLH
Target Name	STAT3
Modification	Phospho-Tyr705
Alternative Names	APRF; Acute-phase response factor; HIES


Application Details

Predicted MW: 88kd


Western blotting: 1:500~1:1000

Immunohistochemistry: 1:50~1:100


Images




Western blot analysis of extracts from HeLa cells untreated or treated with IFN α using STAT3(Phospho-Tyr705) Antibody #11045.



Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using STAT3 (Phospho-Tyr705) Antibody #11045 (left) or the same antibody preincubated with blocking peptide #51045 (right).



Immunohistochemical analysis of paraffin-embedded human Lung carcinoma tissue using STAT3 (Phospho-Tyr705) Antibody #11045.



untreated

IFN treated

Immunofluorescence staining of methanol-fixed MEF cells untreated or treated with IFN using STAT3 (Phospho-Tyr705) Antibody #11045.

Descriptions

Immunogen	Peptide sequence around phosphorylation site of tyrosine 705 (A-P-Y(p)-L-K) derived from Human STAT3.
Specificity	The antibody detects endogenous level of STAT3 only when phosphorylated at tyrosine 705.
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.
Formulation	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg ²⁺ and Ca ²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.
Accession NO.	Swiss-Prot: P40763NCBI Protein: NP_003141.2

Related Information

Transcription factor that binds to the interleukin-6 (IL-6)-responsive elements identified in the promoters of various acute-phase protein genes.

Activated by IL31 through IL31RA.

Fan G, et al. (2003) J Biol Chem. 278(52): 52432-52436.

Barry FA, et al. (2003) FEBS Lett. 553(1-2): 173-178.

Welsh, et al. (1996) Trends Cell Biol. 6: 274-279.

Srivastava A K, et al. (1998) Mol Cell Biochem. 182: 135-141.

Published Papers

Emilio GarcB`B a-Prieto, AdriB`B'n GonzB`B'lez-LB`B pez, Sandra Cabrera el at., Resistance to Bleomycin-Induced Lung Fibrosis in MMP-8 Deficient Mice Is Mediated by Interleukin-10. , PLoS ONE, 5(10): e13242(2010)

[PMID:20949050](https://pubmed.ncbi.nlm.nih.gov/20949050/)

Feng-Ze Wang, Peng-Jiao, Na-Na Yang el at., PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells, Toxicology Letters, 220:150B`C 156(2013)

[PMID:23639247](#)

H Yamaguchi, J Zhu, T Yu et al., Low-level bisphenol A increases production of glial fibrillary acidic protein in differentiating astrocyte progenitor cells through excessive STAT3 and Smad1 activation., *Toxicology*, 226:131-142(2006)

[PMID:16860915](#)

Jian-Guo Zhang, Jing Zhao, Yan Xin et al., Significance and relationship between Cripto-1 and p-STAT3 expression in gastric cancer and precancerous lesions., *World J Gastroenterol*, 16(5): 571B-C577.(2010)

[PMID:20128024](#)

Libing Ma, Jinxiu Li, Guyi Wang et al., Atrial natriuretic peptide suppresses Th17 development through regulation of cGMP-dependent protein kinase and PI3K-CaK signaling pathways., *Regulatory Peptides*., 181:9B-C16(2013)

[PMID:23327998](#)

Takuya Takeichi, Kazumitsu Sugiura, Yoshinao Muro et al., Overexpression of LEDGF/DFS70 Induces IL-6 via p38 Activation in HaCaT Cells, Similar to that Seen in the Psoriatic Condition., *Journal of Investigative Dermatology*, 130(12):2760-2767(2010)

[PMID:20631726](#)

Note: This product is for in vitro research use only and is not intended for use in humans or animals.